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Abstract
Tumor cells of classical Hodgkin lymphoma (cHL) are characterized by a general loss of B cell phenotype, whereas antigen
presenting properties are commonly retained. HLA class I is expressed in most EBV+ cHL cases, with an even enhanced
expression in a proportion of the cases. Promyelocytic leukemia protein (PML) and special AT-rich region binding protein 1
(SATB1) are two global chromatin organizing proteins that have been shown to regulate HLA class I expression in Jurkat
cells. We analyzed HLA class I, number of PML nuclear bodies (NBs) and SATB1 expression in tumor cells of 54 EBV+ cHL
cases and used 27 EBV2 cHL cases as controls. There was a significant difference in presence of HLA class I staining between
EBV+ and EBV2 cases (p,0.0001). We observed normal HLA class I expression in 35% of the EBV+ and in 19% of the EBV2
cases. A stronger than normal HLA class I expression was observed in approximately 40% of EBV+ cHL and not in EBV2 cHL
cases. 36 EBV+ cHL cases contained less than 10 PML-NBs per tumor cell, whereas 16 cases contained more than 10 PML-
NBs. The number of PML-NBs was positively correlated to the level of HLA class I expression (p,0.01). The percentage of
SATB1 positive cells varied between 0% to 100% in tumor cells and was inversely correlated with the level of HLA class I
expression, but only between normal and strong expression (p,0.05). Multivariable analysis indicated that the number of
PML-NBs and the percentage of SATB1+ tumor cells are independent factors affecting HLA class I expression in EBV+ cHL. In
conclusion, both PML and SATB1 are correlated to HLA class I expression levels in EBV+ cHL.
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Introduction
Classical Hodgkin lymphoma (cHL) is characterized by a
minority of B cell derived tumor cells, named Hodgkin Reed-
Sternberg cells (HRS cells) and an abundant reactive infiltrate.
Despite the loss of B cell phenotype [1], HRS cells often retain
their professional antigen presenting phenotype, including expres-
sion of human leukocyte antigens (HLA). They also express
transporters of antigenic peptides (TAP1, TAP2), CD74, and
tapasin required for proper antigen presentation, as well as co-
stimulatory (B7, CD40, CD70) and cell adhesion molecules
(ICAM-1 and LFA-3) [2].
Epstein Barr virus (EBV) is present in the tumor cells in
approximately 30% of the cHL patients in Western Europe and
plays a causal role in cHL pathogenesis [3]. The human leukocyte
antigen (HLA) is a crucial component of the human immune
system as it presents antigens to T cells. HLA class I restricted
CD8+ cytotoxic T-cell (CTL) responses are known to target EBV
infected cells through cell-mediated immunity [4]. HLA class I
expression is retained in HRS cells in ,70% of the EBV+ cHL
cases [5]. This is remarkable, since HLA class I restricted immune
responses to EBV derived antigenic peptides should be detrimental
to EBV+ HRS cells. Previous observations showed an enhanced
HLA class I staining intensity in a proportion of the EBV+ cHL
cases as compared to the surrounding lymphocytes [6,7]. In
contrast, only ,15% of the EBV2 cases retain HLA class I
expression and positive cases showed a staining intensity similar to
lymphocytes in the reactive infiltrate [5].
Promyelocytic leukemia protein (PML) and special AT-rich
region binding protein 1 (SATB1) are two proteins that have been
shown to regulate HLA class I expression. PML is the main
component of nuclear bodies (NBs). PML-NBs are discrete nuclear
foci with a diameter of 0.2 to 1.0 mm. They are present in the
nuclei of most mammalian cells. PML-NBs are dynamic nuclear
matrix-associated domains that recruit a variety of proteins and
regulate many nuclear functions such as DNA replication,
transcription and epigenetic modifications (reviewed in [8]). There
are 5 to 30 PML-NBs per nucleus depending on the cell type, cell
cycle phase and differentiation stage [9]. PML can be processed
into seven different transcripts resulting in protein isoforms that
have variable C-termini [10]. PML-NBs associate with the HLA
locus and other transcriptionally active genomic regions [11,12].
PML induces the expression of HLA class I heavy chains and b2-
microglobulin at the level of transcription, thereby restoring
defective antigen presentation in lung cancer cell lines [13]. Down
regulation of PML results in a reduced HLA-A (classical antigen
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presenting HLA class I) but an enhanced HLA-G (non-classical,
non-antigen presenting HLA class I) expression in Jurkat cells [14].
SATB1 is highly abundant in T cells and acts as a global
chromatin organizer. It is required for the assembly and
maintenance of a higher-order chromatin loop architecture and
it consequently regulates gene expression [15,16,17]. SATB1
partially resides within PML-NBs and has been shown to organize
the HLA class I locus into distinct loops. Silencing of SATB1 in
Jurkat cells results in an enhanced expression of HLA-A, HLA-G,
HLA-H and HCG4P6 [14].
The mechanism of the altered HLA class I expression levels
(stronger than normal or lost) observed in HRS cells in part of the
EBV+ cHL cases is currently unknown. In this study, we
investigated a possible association between PML-NBs, SATB1
and HLA class I expression in the HRS cells of EBV+ cHL.
Materials and Methods
Patients
We selected 54 primary EBV+ cHL cases and as a control 27
random primary EBV2 cHL cases [18]. All cases were diagnosed
between 1987 and 2009. The age at diagnosis ranged from 7 to 94
years. Tissues were retrieved from the tissue bank of the Pathology
Department, University Medical Center Groningen. All diagnoses
were established according to the classification guidelines of the
World Health Organization [19]. The protocol was approved by
the medical ethics board of the University Medical Center
Groningen [18]. All protocols were carried out in accordance
with the Declaration of Helsinki.
Immunohistochemical Staining and Scoring of HLA Class
I, PML-NBs and SATB1
4-mm thick paraffin sections were deparaffinized by xylene and
rehydrated through a graded ethanol series. Tissue sections were
incubated with 0.3% hydrogen peroxide for 30 min to block
endogenous peroxidase and heated in 1 mM Tris/EDTA solution
(pH 9.0) for antigen retrieval. The slides were washed with PBS,
and incubated with the primary antibodies against HLA class I,
ß2-microglobulin, PML and SATB1 (Table S1). The PML
antibody detects all PML isoforms. The surrounding infiltrate
served as a positive internal control, while PBS without primary
antibody served as a negative control. Positive staining was
visualized with 3,3-diaminobenzidine (DAB) after incubation with
secondary and tertiary antibodies. Sections were counterstained
with hematoxylin.
HLA class I heavy chain staining was scored for each case side
by side with ß2-microglobulin staining. The surrounding inflam-
matory cells were used as a reference for assessing the staining
intensity. The staining intensity was scored as normal, i.e. similar
to reactive lymphocytes, or strong, i.e. stronger than the reactive
lymphocytes. Cases without membranous staining were scored as
negative. For PML, we scored HRS cells based on the average
number of PML-NBs in the nuclei of at least 20 HRS cells. The
number of small discrete foci in the nucleus of HRS cells was
counted. Initially, four scoring categories were used (average
number of PML-NBs ,6, 6–10, 11–15 or .15). Because the
number of cases in the ,6 and .15 categories were quite small,
cases were grouped into two categories; with 10 or less PML-NBs
per cell or .10 PML-NBs per cell (per 4 mm tissue section). In
three random cases with ,5 PML-NBs per nucleus and three
random cases with .15 PML-NBs per nucleus we measured the
nuclear surface area of 20 individual tumor cells in each case (120
tumor cells in total) by Aperio ImageScope software v11.1 after
digitally capturing the slides (Aperio Scanscope). For SATB1, we
scored the nuclear staining intensity and the percentage of SATB1
positive HRS cells. If there was no nuclear signal in tumor cells, we
defined them as negative. If HRS cells stained weaker than the
surrounding lymphocytes, we defined them as weakly positive. If
HRS cells and surrounding cells had the same or a (slightly)
stronger intensity as the surrounding infiltrating cells, we defined
them as positive.
Statistical Analysis
Differences between HLA class I expression defined subgroups
were evaluated by the Chi-square test or Fisher exact test. The
Kruskal-Wallis test and post-hoc Dunn’s multiple comparison tests
were used to test for statistically significant differences in age
distribution and percentages of SATB1 positive HRS cells.For
SATB1 staining intensity negative and weakly positive scores were
grouped together. Linear regression analysis was used to evaluate
whether the number of PML-NBs per nucleus was correlated to
the nuclear surface area. Ordinal regression was used for
multivariable analysis of factors contributing to HLA class I
expression (factors with a p-value ,0.1 in univariable analysis
were included). P values less than 0.05 were considered to be
significant. SPSS 20.0 was used for the analyses.
Results
HLA Class I Expression and Patient Characteristics in
Relation to EBV Status
EBV+ tumor cell status was associated with mixed cellularity
subtype and age (Table S2). Representative cases with negative,
normal and strongly positive HLA class I staining in HRS cells are
shown in Fig. 1A–C. HLA class I staining results were consistent
with the ß2-microglobulin staining results in all cases (data not
shown). In the EBV2 group, none of the cases showed a strong
positive staining, 5 cases showed a normal staining intensity and 22
cases were negative for HLA class I. In the EBV+ group, 21 cases
stained strongly positive, 19 showed a normal intensity and 14
cases were negative for HLA class I. This difference in HLA class I
staining pattern was significantly different (P,0.0001; Table S2).
Age, gender and clinical stage had no correlation with tumor cell
HLA class I staining intensity in the EBV+ cHL patients.
Significant differences were observed in the proportion of HLA
class I negative, normal and strong positive cases between
histological subtypes (P = 0.03, Table 1). All negative cases were
of the nodular sclerosis subtype.
PML Staining in Relation to HLA Class I Expression in
EBV+ cHL
The PML antibody stained PML-NBs as randomly distributed
discrete nuclear dots in virtually all nuclei in the tissue. There was
no diffuse nuclear PML staining. To correlate HLA class I to
PML, a known regulator of HLA class I overexpression, the
average number of PML-NBs per HRS cell was scored in EBV+
cHL (Table S3). Representative cases are shown in Fig. 1D and
1E. 38 cHL cases had an average of #10 PML-NBs per cell, while
16 cases showed an average of .10 PML-NBs per cell. The
percentage of EBV+ cHL cases with .10 PML-NBs was
significantly different between HLA class I groups, with the lowest
frequency in HLA class I negative cases (1 out of 14, i.e. 7%), an
intermediate frequency in HLA class I normal (3 out of 19, i.e.
16%) and the highest percentage in HLA class I strong positive (12
out of 21, i.e. 57%) cHL cases (p = 0.002, Fig. 2A). Post-hoc test
indicated that the percentage of EBV+ cHL cases with .10 PML-
NBs significantly differed between HLA class I negative and strong
positive (P = 0.004) and between normal and strong positive cHL
PML-NBs, SATB1 and HLA class I in EBV+ cHL
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cases (P = 0.01). Strikingly, the 7 cases with the highest number of
PML-NBs per HRS cell all had a strongly positive HLA class I
staining. Thus, a high number of PML-NBs in HRS cells is
correlated with enhanced HLA class I expression in EBV+ cHL.
To explore if the number of PML-NBs counted in a 4 mm tissue
section is related to the size of the nucleus, we correlated the
number of PML-NBs to the nuclear surface area in 20 individual
tumor cells per case in 6 different cases (3 cases with low PML-NB
numbers and 3 with high PML-NB numbers). The surface area of
HRS cell nuclei in 4 mm tissue sections ranged from 66 to 412 mm2
and the number of PML-NBs per nucleus ranged from 0 to 40. A
weak negative correlation was observed with bigger nuclei having
slightly less PML-NBs (p = 0.01, r2 = 0.05, Figure 2B). Considering
HRS cell nuclei as a sphere, we estimate that there are close to
Figure 1. Representative immunostaining results of HLA class I, SATB1 and PML-NBs. Arrows indicate the HRS cells. (A) HLA class I
negative case. There is no membranous staining between adjacent HRS cells, while membranes of surrounding cells were positive. (B) HLA class I
positive case. Several adjacent HRS cells show positive membranous staining at the same intensity as the surrounding lymphocytes. (C) cHL case with
a strongly positive HLA class I staining. Staining intensity of HRS cells is more pronounced than the intensity of the surrounding lymphocytes. (D) cHL
case with an average of #10 PML-NBs per cell. One HRS cells with 4 tiny PML-NBs in the nucleus is shown. (E) cHL case with an average of .10 PML-
NBs per cell. A representative HRS cell with more than 20 PML-NBs in the nucleus is shown. (F) cHL case without nuclear SATB1 staining in HRS cells.
(G) Weakly positive nuclear SATB1 staining in HRS cells. (H) Positive nuclear SATB1 staining in HRS cells.
doi:10.1371/journal.pone.0072930.g001
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zero to up to 170 PML-NBs in a complete HRS cell nucleus. In
contrast, we saw on average only 3 to 5 PML-NBs per lymphocyte
nucleus in the reactive infiltrate.
SATB1 Staining in Relation to HLA Class I Expression in
EBV+ cHL
The percentage of SATB1 positive HRS cells varied from 0–
100% in EBV+ cHL. Representative cHL cases with negative,
weakly positive and positive SATB1 nuclear staining are shown in
Fig. 1F–H. Weak SATB1 staining coincided with a highly variable
percentage of SATB1 positive HRS cells, while positive SATB1
staining was related to higher percentages of SATB1 positive HRS
cells (usually .50%). HLA class I results were compared to both
the percentage and staining intensity of SATB1+ HRS cells. We
observed a significant difference in the percentages of SATB1
positive cells between the HLA class I negative, normal and
strongly positive groups (median 65%, 100% and 40%, p = 0.046,
Fig. 2C) and post-hoc analysis showed that this was caused by the
difference between normal and strong HLA class I staining. In the
EBV+ group, 30 cases stained positive, whereas 24 cases were
negative or showed a weak staining for SATB1. There was a
significant difference of SATB1 staining intensity among HLA
Table 1. Statistical analysis of the correlation of clinicopathological characteristics, SATB1 and PML-NBs with HLA class I staining
patterns in EBV+ cHL (n = 54).





Negative normal strong p value p valued
n % n % n %
Age, median
median 22 49 56 0.094a 0.116
(min-max) (8–72) (8–88) (7–94)
Age, year
0–14 3 33.3 3 33.3 3 33.3
15–44 7 41.2 5 29.4 5 29.4 N.S.b –
45–64 3 18.8 6 37.5 7 43.8
.= 65 1 8.3 5 41.7 6 50.0
Gender
M 6 18.2 12 36.4 15 45.4 N.S.b –
F 8 38.1 7 33.3 6 28.6
Clinical stage
I 1 7.1 5 35.7 8 57.1
II 7 41.2 5 29.4 5 29.4 N.S.c –
III 6 46.2 3 23.1 4 30.8
IV 0 0.0 1 100.0 0 0.0
unknown 0 0.0 5 55.6 4 44.4
Histological subtype
Nodular Sclerosis 14 40.0 8 22.9 13 37.1 0.026c 0.093
Mixed Cellularity 0 0.0 5 50.0 5 50.0
LR/LD/NOS 0 0.0 6 66.7 3 33.3
Number of PML-NBs
0–10 PML-NBs 13 34.2 16 42.1 9 23.7 0.002b 0.008
.10 PML-NBs 1 6.3 3 18.8 12 75.0
% of SATB1+ HRS cellse
Median 65 100 40 0.046a 0.024
(min-max) (0–100) (0–100) (0–100)
SATB1 staining intensity
negative/weakly positive 8 33.3 4 16.7 12 50.0 0.039b –




dOrdinal regression analysis for factors with a p value ,0.1 in univariable analysis;
eSATB1 staining intensity was left out of the model since it correlates to % of SATB1+ HRS cells. N.S., not significant. LR, lymphocyte rich. LD, lymphocyte deleted. NOS,
not otherwise specified.
doi:10.1371/journal.pone.0072930.t001
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class I negative, normal and strong positive groups (P = 0.039,
Table 1). Post-hoc analysis indicated that this effect is due to a
significant difference between HLA class I normal and strong
positive groups, the latter being associated with negative/weakly
positive SATB1 staining. There was no statistical difference
between HLA class I negative vs. normal or negative vs. strong
cases.
Multivariable Analysis of Patient Characteristics, PML-NBs
and SATB1 in Relation to HLA Class I Expression in EBV+
cHL
To investigate the possibility that the effects of PML-NBs and
SATB1 expression depend on each other or on other affecters of
HLA class I expression, we performed a multivariable analysis.
Because the percentage of SATB1+ HRS cells and the SATB1
staining intensity are mutually dependent, we only fitted the
percentage of SATB1+ HRS cells into the model. The number of
PML-NBs was the most significant independent factor correlating
with HLA class I staining (p = 0.008), whereas the percentage of
SATB1 also proved to be an independent variable (p = 0.024,
Table 1). Age and cHL subtype were no independent contributors
to HLA class I expression.
Discussion
The mechanism of enhanced expression of HLA class I in
EBV+ cHL, as well as the down regulation of HLA class I in part
of EBV+ and EBV2 cHL is unclear. In this study, we showed that
the enhanced HLA class I expression in EBV+ cHL is positively
associated with the number of PML-NBs and inversely correlated
with the nuclear staining intensity and the percentage of SATB1
positive tumor cells. There was no association between HLA class
I negative cHL cases and either PML or SATB1, indicating that
other mechanisms contribute to down regulation of HLA class I
expression, e.g. loss of the HLA loci, aberrant transcription factor
expression or epigenetic modifications.
In our case series, retention of HLA class I expression was
observed in ,20% of EBV2 and ,75% of EBV+ cHL. An even
stronger than normal HLA class I expression was seen in half of
the HLA class I positive EBV+ cHL cases. It is enigmatic how
tumor cells benefit from retained or enhanced HLA class I
expression in the face of anti-EBV immune responses. It is known
that during primary lytic EBV infection of a naı¨ve B cell the HLA
class I antigen presentation pathway is strongly inhibited by lytic
EBV proteins (BNLF2a, BNLF5 and BILF1) [20,21,22]. However,
when lytic infection switches to latent infection, the expression of
HLA class I is restored. Moreover, it has been reported that LMP1
can enhance HLA class I expression levels to higher than normal
[23]. In EBV+ cHL with high HLA class I expression there is an
increased number of CTLs in the reactive infiltrate, suggesting
that antigens are presented in the context of HLA class I.
However, these CTLs are usually not in the close vicinity of HRS
cells [6]. Previous studies from our group showed a strong
association of two HLA-A types with EBV+ cHL [24,25]. HLA-
A*01 is a risk type and has low affinity for LMP1 and LMP2
derived antigenic peptides, whereas HLA-A*02 is a protective type
that has a relatively high affinity for LMP1 and LMP2 derived
antigenic peptides [26,27]. Thus, lack of the HLA-A*02 type
might explain why EBV+ HRS cells with HLA class I expression
are not recognized and targeted by cytotoxic T cell mediated
antitumor responses. In addition, HRS cells express immunosup-
pressive cytokines, such as TGF-b and IL-10 which can inhibit the
cytotoxicity of these CTLs [28,29]. A possible advantage of HLA
class I expression would be inhibition of natural killer (NK) cells.
We have previously shown that HLA class I negative HRS cells
commonly express the NK cell inhibiting cell surface protein
HLA-G instead [5]. Whether EBV+ HRS cells would benefit from
an even increased HLA class I expression and what mechanism(s)
would be involved remain open questions.
Enhanced HLA class I expression was correlated with an
increased number of PML-NBs in EBV+ HRS cells. This increase
was not due to an increase in size of HRS cell nuclei. In normal B
and T lymphocytes the number of PML-NBs ranged from 3 to
5 per nucleus. We estimate that in HRS cells the number of PML-
NBs ranges from close to zero to up to 170 PML-NBs per nucleus.
The positive correlation of the number of PML-NBs with HLA
class I expression is consistent with the results of a previous study
showing that inhibition of PML-III and PML-V isoforms resulted
in a down regulation of the expression of a distinct set of HLA class
I genes in Jurkat cells [14]. Overexpression of LMP1 in lung
Figure 2. PML and SATB1 staining results in relation to HLA class I in EBV+ cHL (n=54). (A) The percentage of EBV+ cHL with .10 PML-
NBs significantly increased from HLA class I negative to normal and strong positive cHL cases (p = 0.002, Chi-square). Post-hoc test indicated that the
percentage of EBV+ cHL cases with.10 PML-NBs differs significantly between HLA class I negative and strong positive or normal and strong positive
cHL cases. (B) Correlation of the number of PML-NBs with nuclear size in 120 HRS cells from 6 different cases (three with low number and three with a
high number of PML-NBs). There is a weak negative correlation between the number of PML-NBs and size of the tumor cell nucleus (P = 0.01). (C) The
percentage of SATB1 positive HRS cells in EBV+ cHL cases with negative, normal or strong HLA class I staining pattern differ significantly (p = 0.046,
Kruskal-Wallis test). Dunn’s multiple comparison test indicated a significant difference specifically between the HLA class I normal and strong staining
groups. The median SATB1 percentage is indicated in each group. White symbols indicate the cases with no or weakly positive SATB1 staining,
whereas black symbols indicate cases with positive SATB1 staining.
doi:10.1371/journal.pone.0072930.g002
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epithelial cells induced PML protein expression and increased
both the size and number of PML-NBs [30]. Considering that
LMP1 can increase HLA class I in Burkitt lymphoma [23], we
propose that this LMP1-mediated increase of HLA class I
expression might be induced via induction of the number of
PML-NBs.
We showed an inverse correlation between SATB1 and
enhanced HLA class I expression in EBV+ cHL cases. This is
consistent with previous findings in Jurkat cells showing that
silencing of SATB1 increases HLA class I expression at the mRNA
level from normal to strong [14]. Low SATB1 expression in EBV+
cHL was observed previously by microarray profiling of micro-
dissected HRS cells [31]. Of note, SATB1 staining was more
variable in HLA class I negative cases and not stronger in
comparison to cases with normal expression. Therefore, there is no
evidence in our study that increased SATB1 expression is
associated with down regulation of HLA class I. We conclude
that lack of SATB1 is only associated with stronger than normal
HLA class I staining in EBV+ cHL.
Since SATB1 partially resides in PML-NBs we were interested
to see whether these two factors have an independent effect on
HLA class I expression. Multivariable analysis indicated that the
number of PML-NBs is the most significant independent factor
correlating with HLA class I expression in EBV+ cHL, while the
percentage of SATB1+ tumor cells also had an independent effect.
Although sometimes a subtle dot-like nuclear SATB1 staining
could be observed, diffuse SATB1 nuclear staining prohibited
scoring of SATB1 containing PML-NB. It is therefore unclear if
the effect of SATB1 is caused by SATB1 located in PML-NBs, by
diffuse SATB1 or by both.
In conclusion, strongly enhanced HLA class I expression in
EBV+ cHL is positively correlated with the number of PML-NBs
and negatively correlated with SATB1 at the protein level. SATB1
and PML may play an important role in up regulating HLA class I
expression in EBV+ cHL.
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